ACHV

Business Context and Reporting Period

Company: OncoGenex Pharmaceuticals, Inc. (formerly Sonus Pharmaceuticals, Inc. following a reverse takeover of OncoGenex Technologies Inc. in August 2008).

Reporting Period: Quarterly Report (Form 10-Q) for the period ended September 30, 2009.

Business Overview: A development-stage biopharmaceutical company focused on cancer therapies. The company has no product revenue and relies on funding from equity offerings, partnerships, or debt. Key product candidates include OGX-011 (prostate cancer), OGX-427 (solid tumors), and OGX-225.

Key Financial Metrics

Note: The company reported a cumulative deficit of $57.4 million since inception.

Material Changes vs. Prior Period

• Operating Expenses: For the nine months ended September 30, 2009, Research and Development (R&D) expenses increased to $6.8 million from $3.6 million in the prior year period. This increase was driven by development costs for OGX-011 and OGX-427, higher employee expenses, and facility costs from the reverse takeover. General and Administrative (G&A) expenses rose to $2.7 million from $2.2 million due to public company operating costs.
• Other Income: Other income increased to $79 thousand for the nine months ended September 30, 2009, compared to a $54 thousand expense in the prior year, primarily due to gains on equipment sales and foreign exchange gains.
• Financing Activity: The company raised approximately $9.3 million in net proceeds from a registered direct offering of common stock in July 2009, significantly offsetting operating cash burn.
• Restructuring: A change in estimate regarding excess facility lease liabilities resulted in a $494,000 R&D expense charge in June 2009.

Outlook, Risks, and Management Commentary

• Liquidity: As of September 30, 2009, the company held $12.5 million in cash, cash equivalents, and short-term investments. Management believes this is sufficient to fund operations into the fourth quarter of 2010, covering Phase 2 follow-ups and Phase 3 preparation for OGX-011.
• Capital Needs: The company requires additional funding to support planned Phase 3 clinical trials for OGX-011 in castrate-resistant prostate cancer (CRPC). Funding is sought through partnerships, licensing, or equity/debt offerings.
• Clinical Progress: Phase 2 results for OGX-011 showed a 6.9-month survival advantage when combined with docetaxel. Two Phase 3 trials are planned (survival benefit and pain palliation). Phase 1 trials for OGX-427 are ongoing.
• Risks: Key risks include the inability to secure additional funding, failure of clinical trials, regulatory delays, and the uncertainty of exiting or subleasing excess office space in Bothell, Washington (liability of $1.4 million).
• Employment Agreements: New employment agreements were executed in November 2009 for the CEO, CFO, and CMO, including significant severance and change-in-control provisions.

Investor Verification Checklist

• Cash Runway: Verify if the $12.5 million cash balance is sufficient to reach the next funding milestone given the burn rate of ~$9.2 million per nine months.
• Partnership Status: Confirm the status of partnership discussions for OGX-011, which is critical for funding Phase 3 trials.
• Lease Liability: Assess the company's progress in subleasing or exiting the Bothell facility to mitigate the $1.4 million excess facility liability.
• Regulatory Path: Review the FDA Special Protocol Assessment (SPA) agreements for the two planned Phase 3 trials to ensure alignment with management's timeline.
• Dilution Risk: Monitor future equity offerings required to fund operations, noting the recent issuance of 475,000 shares in July 2009.